Continued Peer Reviewer Representation Consultant Speaker s Bureau Ownership/ Partnership/ Principal Personal Research Institutional, Organizational, or Other Financial Benefit Expert Witness E. Magnus Ohman Content Reviewer ACCF/ AHA Task Force on Practice Guidelines AstraZeneca Bristol-Myers Squibb Boehringer Ingelheim Gilead Sciences Merck Pozen Sanofi-aventis Boehringer Ingelheim Gilead Sciences None Daiichi-Sankyo Datascope Eli Lilly None None John D. Rutherford Content Reviewer None None None None None None George A. Stouffer Content Reviewer None None None None None Defendant, review of malpractice claim, 2010 Mathew Williams Content ACCF Interventional Scientific Council Edwards Lifesciences Medtronic None None None None None This table represents the relationships of reviewers with industry and other entities that were disclosed at the time of peer review and determined to be relevant. It does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of 5% of the voting stock or share of the business entity, or ownership of $10 000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person s gross income for the previous year. A relationship is considered to be modest if it is less than significant under the preceding definition. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. Names are listed in alphabetical order within each category of review. 